He said: “Far too few businesses are focused on true innovation. But Endomag has demonstrated the successful translation of technology from a university environment into the market. By engaging with clinicians from its formation, Endomag ensured that its technology addressed a clear market need.
“The company has treated successfully more than 6,000 breast cancer patients across 20 countries and, by continuing to invest in its R&D, Endomag now aims to address, and possibly treat, many more cancers such as melanoma, prostate, bladder and lung.”
Endomag has also opened a US office in Austin, Texas, in preparation for expansion into the American market.
The company started a pivotal US trial of its innovative breast cancer system Sentimag® and Sienna+® this January, and is expecting significant continued growth through additional product introductions and international sales expansion.
Endomag was revealed as a finalist for the UK’s most prestigious engineering award last month, one of three companies up for the MacRobert Award from the Royal Academy of Engineering.
The award is the longest-running national prize for engineering and has a reputation for spotting the next big thing in the tech sector. Entries are judged on being outstanding innovations, with proven commercial promise and tangible societal benefit and the winner will be announced on 16 July.
Dr Eric Mayes, CEO at Endomag, said: “Our systems are fast becoming known amongst surgeons as the ‘next standard of care’. Sales in Europe and Australasia have enabled the business to achieve triple-digit revenue growth over the past three years, and we are well positioned to take our products even further afield to achieve our mission of ‘bringing cancer care to everyone, everywhere’.”
Endomag is dedicated to improving the global standard cancer care for everyone, everywhere, by developing a new, effective clinical platform that uses safe magnetic fields to power diagnostic and therapeutic devices.
Endomag’s first approved products are the Sentimag® and Sienna+®, CE-approved for marketing and sales in Europe, and TGA-approved for Australasia. Sienna+® is a magnetic tracer injected into the body and the Sentimag® is used to track its presence, locating lymph nodes as part of a sentinel lymph node biopsy (SLNB) procedure.
By avoiding the need for traditional radioactive isotopes in sentinel lymph node biopsy, Sentimag® and Sienna+® improve workflow and lower costs, enhance patient comfort and quality of life, and provide a better standard of care available to everyone, everywhere.
Visit www.endomag.com
*******
PR media contacts: Nicola Collenette/ Charlie Hopkinson
E: nicola.collenette@mobas.com / charlie.hopkinson@mobas.com
T: +44 (0)1223 841699 / +44(0)7711 372820
_____________________________________